Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Oxytocin for Vaginal Atrophy
NCT01432470Phase 2Completed
- Sponsor
- Peptonic Medical
- Start
- Aug 2010
- Primary completion
- Jun 2011
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in vaginal atrophy (2 arms), sponsored by Peptonic Medical. Primary endpoint: The Maturation Value (MV) at 12 weeks. Started Aug 2010; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
vaginal atrophy
Beyond the preview
Go deeper on NCT01432470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01432470.